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Māori are the indigenous people of New Zealand (NZ), comprising approximately 15% of the national 
population. A major disparity exists between 
Māori and non-Māori in cardiovascular 
mortality, which remains the leading 
cause of premature death and disability 
in New Zealand.1,2 Furthermore, recent 
health statistics indicate that those living in 
rural areas are worse off than urban New 
Zealanders, including for prevalence of 
ischaemic heart disease.3 Rural Māori have 
a shorter life expectancy than urban Māori, 
with 1.2 years difference for women and 1.5 
years difference for men.3 The combination 
of resource accessibility and ethnic disparities 
may additionally disadvantage rural Māori 
communities with respect to health outcomes. 
Recent data on cardiovascular disease (CVD) 
and its risk factors in Māori has been obtained 
from mortality or hospital statistics,1,4 from 
diagnoses in general practice,5 and in 
urban Auckland communities,6-10 but we 
lack information about the state of Māori 
cardiovascular health in rural communities. 
In addition, disease rates and risk factors 
in indigenous population groups may be 
underestimated if these groups do not have 
equivalent access to health care or CVD 
screening. This underestimation will occur 
in studies based on clinical databases. It will 
also occur in population studies that rely on 
self-report of doctor-diagnosed conditions, 
such as the New Zealand Health Survey.11 
A study in 196212 assessed coronary heart 
disease as part of a wider health survey of 
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the rural Tuhoe iwi (tribe), disclosing a spectrum of metabolic 
ailments and undiagnosed coronary disease. Since then, mortality 
from premature coronary heart disease in NZ peaked in 1965-69 
and has since fallen, largely associated with the declining population 
trends in systolic blood pressure, total blood cholesterol and smoking 
prevalence.13 Therefore, it is timely to reassess the current CVD 
health status and levels of treatment for CVD risk for Māori living 
in a rural community. 
The Hauora Manawa/ Community Heart Study is a cohort study 
of heart disease in NZ, based on random selection from electoral 
rolls, sampled to be representative of the age and gender profiles 
within each participating community. The study has documented 
cardiovascular risk in Māori and will monitor the implementation 
of treatment programs, interventions, and outcomes for study 
participants over five years of follow up. Clinical diagnoses were 
established at baseline for all participants at screening clinics to 
determine levels of both diagnosed and undiagnosed risk factors. 
Baseline data from Māori living in a rural community in the Wairoa 
district are presented here.
Methods
Participants
The Wairoa District is in rural Hawkes Bay on the east coast of 
the North Island of NZ with 61% of the population identifying 
as of Māori ethnicity. The Community Heart Study was carried 
out in Wairoa from May 2007 to December 2007. Full details of 
kaupapa Māori methodology, sample selection, recruitment and 
interviewing processes are published elsewhere.14 In brief, from 
the Wairoa District electoral roll, 541 participants, aged between 
20 to 64 years, stratified by age and sex, were randomly selected 
among those who identified as being of Māori descent. Multiple 
recruitment approaches included invitation letters, follow-up 
letters, follow-up phone calls, media releases and door-knocking. 
A total of 252 Māori participants who self-identified as being of 
Māori ethnicity and were within the inclusion criteria attended the 
screening clinics. The overall response rate was 57.6% (95% CI 
53.0, 62.2) and the cooperation rate (participation among those with 
whom contact was established) was 74.7% (95% CI 70.1, 79.3). 
The study was approved by the Multi-Region Ethics Committee 
(Reference MEC/06/03026) and all participants provided written, 
informed consent.
Screening clinics were held at the Wairoa Hospital Outpatients 
clinic from 6 am to 9 pm. All participants completed an interviewer-
administered questionnaire providing demographic, personal and 
family medical history, current medications, smoking status, alcohol 
consumption, physical activity levels and socioeconomic data. 
Physical activity levels were assessed by asking the participant 
whether they were regularly physically active, defined as at least 
30 mins of moderate activity each day for five or more days each 
week. Confirmation of prior diagnoses and current management 
of CVD risk factors were obtained from primary care physicians 
for all participants.
Two blood pressure measurements were taken while seated, 
at least 20 minutes apart, using manual sphygmanometers with 
appropriate cuff sizes. Height, weight, waist and hip measurements 
were taken, body composition analysis performed by bioimpedance 
using the Tanita Body Composition Analyzer, TBF 310 (Tanita Inc, 
Tokyo, Japan) and body mass index (BMI) calculated. The ranges 
for BMI were: healthy range = BMI ≥18.5, <25.0 kg/m2, overweight 
= BMI 25.0 – 29.9 kg/m2 and obese = ≥30.0 kg/m2). Fasting blood 
samples were collected and assayed for full blood differential 
cell counts (Wairoa Hospital Laboratory, Hawkes Bay District 
Health Board); plasma lipid profiles, glucose, insulin, creatinine, 
homocysteine, urate and HbA1c (Canterbury Health Laboratories, 
Christchurch Hospital). 
Smoking status categories were: Current smoker = current smoker 
at screening clinic, Ex-smoker = quit smoking for more than 12 
months (those who had quit less than 12 months were not included in 
these classifications), Never smoker = never smoked in their lifetime. 
A new diagnosis of hypertension and dyslipidaemia was made 
in those with levels above the reference ranges with no prior 
diagnosis and who were not receiving treatment. Hypertension 
was documented at screening if the average of the two blood 
pressure readings gave a SBP >140 mmHg or DBP >90 mmHg. 
Dyslipidaemia was diagnosed if the total cholesterol:HDL-
cholesterol (TC:HDL) ratio was >4.0. 
Normoglycaemic individuals were identified as those with 
glucose levels <6.0 mmol/L. Three methods were used to determine 
insulin resistance (IR) in individuals with no previous diagnosis 
of type-2 diabetes mellitus (DM2) and who were not receiving 
anti-hyperglycaemic medication. Firstly, the Homeostasis Model 
Assessment (HOMA) IR equation was used:
HOMA1-IR = (FPI × FPG)/22.515
(where FPI = fasting plasma insulin and FPG = fasting plasma 
glucose). Insulin resistance by HOMA was defined by any of 
the following criteria: BMI>28.9kg/m2 or HOMA-IR>4.65 or 
a combination of BMI>27.5kg/m2 and HOMA-IR>3.6.16 The 
McAuley formula was also used for determination of insulin 
resistance: 
exponent (3.29 – 0.25ln[fasting insulin]-0.22ln 
[body mass index]-0.28ln[fasting triglycerides].
Values ≤6.3 M / mU / L in normoglycaemic individuals were 
classified as insulin resistant.17 Fasting insulin levels > 12.2 mU/L 
(84.73 pmol/L) was also used as a definition of insulin resistance.17 
Absolute 5-year cardiovascular risk (%) was calculated using the 
Bestpractice© electronic decision support software (Bestpractice©, 
2005–09, Dunedin, NZ). Calculated risk categories were defined as: 
Low risk, <10%; moderate risk, 10-15%; high risk, 15-20%; very 
high risk, >20%. The national guidelines CVD risk charts commence 
risk calculation at age 35 years.18 CVD risk for participants <35 
years was automatically calculated by Bestpractice©. Note that the 
Guidelines recommend a 5% adjustment be added to the CVD risk 
calculation for people of Māori ethnicity, and hence all participants 
in this study had at least 5% CVD risk scores.
The 2004 version of the NZ Cardiovascular Guidelines were in 
current usage at the time of screening and calculations of those 
who were within the risk factor targets for existing morbidities at 
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screening were based on the 2004 Guidelines, since these would 
have been used by doctors at the time of treatment and management. 
Revised 2009 NZ Cardiovascular Guidelines18 have since been 
published and modifications include the deletion of different BMI 
ranges for Māori, Pacific and European individuals, lower targets 
for TC:HDL ratio (4.0 vs 4.5 previously) and LDL-cholesterol (2.0 
vs 2.5 mmol/L previously) and omission of the metabolic syndrome 
as a risk factor. These revised thresholds were applied to determine 
any subsequent, new diagnoses in the cohort.
Statistical analysis
All statistical analyses were performed using SPSS v13.0 
(Chicago, Illinois, US). Data are expressed as mean ± SEM or 
as percentages. Comparisons were carried out using analysis of 
variance or chi-square tests, as appropriate. Age and BMI were 
used as continuous covariates in analysis of variance. Significance 
levels were set as p≤0.05.
Results
Cardiac disease, diabetes and risk factors
The baseline characteristics of the 252 participants who attended 
the screening clinics in Wairoa are shown in Table 1. All except 
five participants were registered with a General Practitioner (GP) 
at the time of screening, with 69% of participants having visited 
their doctor within the last six months and 85% having visited their 
doctor within the last 12 months. 
Estimated five-year CVD risk scores in the cohort (Table 2) were 
63% with low, 21% with moderate, 6% with high and 10% with 
very high CVD risk. The moderate to very high-risk CVD scores 
all occurred in participants aged 40 years and above. The key risk 
factors contributing to the overall CVD risk scores, age, BMI, blood 
pressure, cholesterol and family history were analysed further as 
described below. 
Age is an established risk factor for CVD, and is included in 
the five-year CVD risk calculation. However, while the highest 
overall CVD risk was seen in older individuals, high levels of 
certain individual risk factors were evident in younger age groups. 
For example, males aged 30-34 years had high mean TC: HDL 
cholesterol ratios (5.4 ± 0.5) and blood pressures (systolic, 129 ± 
5.4 mmHg, diastolic 87.7 ± 2.7 mmHg). 
The mean BMI for the cohort was 30.7 kg/m2 (Table 1) with 78% 
having a BMI in either the overweight or obese range. Similarly, 
body composition scales indicated that 20.4% were in the healthy 
range for percent body fat, 25.7% were in the overweight body fat 
range and 51.4% were in the obese range. 
Table 1 – Baseline characteristics of the Wairoa cohort. 
Variables Males 
n=102
Females 
n=150
Total 
n=252
Mean Age (years) 46.7 ± 1.2 45.0 ± 0.9 45.7 ± 0.7
BMI (kg/m2) (n=251) 30.6 ± 0.7 30.8 ± 0.6 30.7 ± 0.5
   Healthy Range (<25.0kg/m2), n (%) 22 (21.4) 33 (22.1) 55 (21.9)
   Overweight (25.0 – 29.0 kg/m2), n (%) 34 (33.0) 42 (28.2) 76 (30.3)
   Obese (>30 kg/m2), n (%) 47 (45.6) 73 (49.0) 120 (47.8)
Waist circumference, cm (n=250)* 101.9 ± 1.71 94.6 ± 1.41 97.5 ± 1.11
Systolic blood pressure (mmHg) 136.2 ± 1.6 127.2 ± 1.6 129.6 ± 1.3
Diastolic blood pressure (mmHg) 87.6 ± 1.0 83.7 ± 1.0 84.4 ± 0.8
Current smoker, n (%) 35(34.3) 72(48.1) 107 (42.5)
Ex-smoker, n (%) 45(44.1) 52(34.7) 97(38.5)
Never smoker, n (%) 22(21.6) 26(17.3) 48 (19.0)
Regularly physically active, n (%) 78 (76.5) 94 (62.7) 172 (68.3)
Plasma glucose, mmol/L (n=217)* 6.1 ± 0.2 5.5 ± 0.1 5.8 ± 0.1
Plasma insulin, pmol/L (n=215)* 64.6 ± 7.1 66.1 ± 4.5 65.6 ± 3.9
HBA1c, % (n=249)* 6.5 ± 0.1 6.2 ± 0.1 6.3 ± 0.07
Total cholesterol, mmol/L (n=217)* 5.2 ± 0.1 5.0 ± 0.1 5.1 ± 0.1
LDL–cholesterol, mmol/L (n=214)* 3.3 ± 0.1 3.1 ± 0.1 3.2 ± 0.1
HDL-cholesterol, mmol/L (n=217)* 1.2 ± 0.03 1.3 ± 0.03 1.2 ± 0.02
Fasting triglycerides, mmol/L (n=217)* 1.7 ± 0.1 1.4 ± 0.1 1.5 ± 0.1
Total cholesterol: HDL ratio (n=214)* 4.4 ± 0.1 4.1 ± 0.1 4.2 ± 0.07
Prior Cardiac History, n (%) 11 (10.8) 8 (5.3) 19 (7.5)
Prior Diagnosis DM2, n (%) 12 (11.8) 15 (10.0) 27 (10.7)
Prior Diagnosis Hypertension, n (%) 27 (26.5) 36 (24.0) 63 (25.0)
Prior Diagnosis High Cholesterol, n (%) 19 (18.6) 17 (11.3) 36 (14.3)
Data expressed as mean ±SEM for all continuous variables.
* Indicates data missing or excluded due to participant not fasting.
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Mean systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) for the cohort are shown in Table 1. Twenty-five per cent 
had been previously told by a doctor they were hypertensive. A 
new diagnosis of hypertension was made in an additional 22% of 
the cohort (n=56). Hence, a total of 47% (n=119) of the cohort had 
either a prior or a new diagnosis of hypertension.
Mean levels of total cholesterol (TC), LDL-cholesterol and TC: 
HDL ratios (Table 1) were all above the recommended ranges set 
by national cardiovascular guidelines.18 Approximately 14% of 
the cohort had been previously diagnosed with dyslipidaemia. At 
screening, 87% of the cohort had elevated fasting TC levels (>4.0 
mmol/L). However, mean HDL-cholesterol levels were within the 
recommended range. To determine a new diagnosis of dyslipidaemia 
in those with no prior diagnosis and who were not receiving lipid-
lowering medications, TC: HDL ratio >4.0 mmol/L was used, 
with 43% of the cohort having a TC: HDL ratio above this level. 
Therefore, 57% of the cohort had either a prior or a new diagnosis 
of dyslipidaemia.
In this cohort, 8% had a history of cardiac disease at screening 
(mean age 56.3 ± 1.7), defined as a history of myocardial infarction, 
angina, heart failure, coronary artery bypass graft (CABG) 
surgery, percutaneous transluminal coronary angiography (PTCA), 
pacemaker, other cardiac intervention or ischaemic stroke. 
The proportion of previously diagnosed type-2 diabetes mellitus 
(DM2) was 11% (Table 1), with the majority aged between 50-59 
years. Among those not diagnosed with diabetes and not receiving 
antihyperglycaemic treatment, a new diagnosis of Impaired Fasting 
Glucose (IFG) was made in 8%, with 2% of the cohort having fasting 
glucose levels >6.9 mmol/L. Also among non-diabetic participants, 
22% had HBA1c levels >6.4% and 25% had fasting insulin levels 
>80 pmol/L.
Of this cohort, 36% fitted the clinical criteria defining Metabolic 
Syndrome. Insulin resistance estimated with the HOMA-IR decision 
rules classified 48% as insulin resistant. Insulin resistance calculated 
using the McAuley formula,17 that incorporates fasting triglyceride, 
fasting insulin and BMI, classified 20% of the cohort as insulin 
resistant. Fasting insulin levels greater than 84.73 pmol/L (12.2 
mU/L) indicated insulin resistance in 15%. 
At screening 43% of the cohort were current smokers and 57% 
were non-smokers (never and ex-smokers) (Table 1). More males 
were ex-smokers (44%) compared to females (35%), however there 
was a trend (p=0.07) for higher calculated number of pack years 
in males than females (6602.4±660.0 vs 5207.0±381.9 pack years 
respectively). 
Family history is a known risk factor for heart disease. Of those 
with a personal cardiac history, 68% reported having first-degree 
family history of CVD. In DM2 patients, 48% reported a first-degree 
family history of DM2. In the cohort overall, including those both 
with and without a personal cardiac history or DM2, the rates of 
first-degree family history of CVD were 52% and first-degree family 
history of DM2 were 45%.
Levels of treatment 
The optimal targets for those with known CVD, CVD risk >15% 
or DM2, according to the NZ CVD Guidelines in use at the time 
of screening were used to assess those achieving treatment targets. 
Among those with a prior cardiac history, 66% had previously 
diagnosed hypertension and dyslipidaemia and 20% had a prior 
diagnosis of DM2. Combined therapies of lipid-lowering and 
antihypertensives were received by 50% of this group. However, 
systolic and diastolic blood pressure targets were achieved in only 
32% and 10% respectively. While total cholesterol and LDL-
cholesterol targets were achieved in only around 20%, TC: HDL 
ratios were within the target range in 68% of this group due to the 
prevalence of HDL-cholesterol above the recommended level (>1.0 
mmol/L) in this community. 
A systolic blood pressure target of 130/80mmHg or less is 
recommended for those with diagnosed hypertension or in the 
high-risk categories of known CVD, diabetes or absolute CVD risk 
>15%.18 Of participants in this group (n=88) approximately half 
(n=43) were treated with antihypertensive medication, with 33% 
achieving both systolic and diastolic target blood pressures. Of those 
not receiving treatment (n=45), 29% were at target for systolic and 
20% for diastolic blood pressure.
Previously-diagnosed high cholesterol was present in 14% at 
screening (n=36), with 58% of those on cholesterol-lowering 
medication (n=21). Of those on medication, targets were achieved 
by 10% for TC, 38% for LDL-cholesterol, 43% for triglycerides, 
and 67% achieved target TC: HDL ratios. Of those not currently 
on medication (n=15), 7% were within target for TC, 7% for LDL-
cholesterol, 53% for triglycerides, while 27% achieved target TC: 
HDL ratios. Those on cholesterol-lowering drugs had significantly 
lower total cholesterol (p=0.014) and LDL-cholesterol (p<0.001) 
compared to participants not on medication, with significantly lower 
triglycerides levels observed in females only (p=0.002).
Among those with previously diagnosed DM2 (n=27), 
approximately two thirds were currently receiving treatment (n=19) 
and more than a third of those with DM2 were receiving both lipid-
lowering and antihypertensive treatments at screening. However, 
glycaemic control (HBA1c level < 7.0%) was achieved in only 
21% of those on treatment. Of treated diabetic patients, 16% were 
within target for systolic and diastolic blood pressure, while targets 
were achieved for TC, LDL-cholesterol and TC: HDL ratios in 11%, 
26% and 55% respectively.
Table 2 - Mean five-year calculated CVD risk scores in 
the rural Wairoa Māori cohort.
Age Males Females All
20 – 29 years (n) 5.4 % (10) 5.1 % (20) 5.2 % (30)
30 – 39 years (n) 6.6 % (23) 6.1 % (33) 6.3 % (56)
40 – 49 years (n) 9.9 % (22) 8.0 % (41) 8.6 % (63)
50 – 59 years  (n) 15.0 % (32) 10.8 % (43) 12.6 % (75)
60 – 65 years (n) 14.6 % (15) 16.7 % (13) 15.6 % (28)
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Discussion 
Within this rural Māori community we have identified high 
levels of undiagnosed CVD risk factors, especially hypertension, 
dyslipidaemia and insulin resistance, despite the majority of 
participants having recently attended their doctor. Furthermore, 
among those being treated for CVD risk factors, recommended 
targets were not achieved for a large proportion. This study 
highlights areas where there is scope for greater risk factor 
management to care for the health of the rural Māori population, 
by greater vigilance of a patient’s risk factors and application of 
the recommendations for screening and risk factor management 
provided in the NZ CVD Risk Guidelines.
This study aimed to determine current levels of both diagnosed 
and undiagnosed risk factors within this indigenous community by 
conducting CVD screening clinics in a sector of the community 
that is often hard to reach. The sampling methodology has been 
previously reported14 and the cohort sampled to be representative of 
age and gender profiles of the Wairoa electorate. The response rate 
at 57.6% and cooperation rate at 74.7% is similar to prior study of 
insulin resistance in an adjacent rural Māori community in which 
screening clinics were also conducted.19
The prevalent CVD risk factors identified in this rural Māori 
cohort were high BMI, hypertension, high cholesterol, smoking 
and a family history of coronary heart disease. Previous prevalence 
studies of CVD and related morbidities in Māori communities 
have reported increased body mass, cholesterol levels, tobacco 
use and sedentary lifestyles as disparate between Māori and non-
Māori.4,5,12,20 In the current study, approximately 70% of the cohort 
reported being physically active at the level recommended by 
national guidelines, compared to the national average of 51.6% for 
men and 51.9% for women in the 45-54 year age-group (around 
the mean age of the Wairoa cohort).11 A review of national physical 
activity surveys reported that Māori are at least as active as European 
New Zealanders.21 Despite this, 80% percent of participants were 
classified as having a BMI above the healthy range (overweight or 
obese) compared to 63% of the general NZ population.11 
Current smoking rates (43%) were similar to recent national trends 
of smoking in Māori populations (45.4%).22 Although national rates 
of smoking have decreased since the first official recording of 36% 
in the mid-1970s, rates among Māori remain higher than in the 
general NZ population (currently 22%). There is a clear need to 
continue to target this risk factor. Since the findings of this study 
were presented to the local District Health Board, two Smoking 
Cessation facilitators have been employed in the Wairoa district.
The percentage of those with a prior cardiac history was 8%, 
markedly higher than the self-reported prevalence of ischaemic 
heart disease of 4.7% in Māori in a national survey.11 Although there 
were small numbers in this subgroup, diagnoses of hypertension and 
high cholesterol were major factors associated with the presence 
of established cardiac disease. The high prevalence of reported 
family history of premature coronary heart disease suggests familial 
genetic predisposition may also be a contributing factor for CVD 
risk in this cohort.
Uncontrolled hypertension is a major risk factor for diseases of 
the heart and blood vessels.23 A quarter of the cohort had diagnosed 
hypertension and an additional 22% of the cohort had high blood 
pressure at screening that had not been picked up previously. Blood 
pressure was elevated above targets in approximately two-thirds of 
the cohort who had a prior diagnosis of hypertension, prior cardiac 
history, DM2 or 5-year CVD risk greater than 15%, including in 
those who were receiving antihypertensive medication. A prior 
workforce study identified that BMI-adjusted means for blood 
pressure halved the BP difference between Māori and Europeans; 
however the difference was still significant, suggesting other 
factors acted as a driving force in increased blood pressure in this 
indigenous group.24
Elevated cholesterol levels increase risk of ischaemic heart 
disease and ischaemic stroke.25 The mean total cholesterol level for 
the Wairoa cohort was 5.1 mmol/L, slightly lower than the levels 
reported in Māori in the Auckland Diabetes Heart and Health Survey 
2002-2003, which reported the mean for Māori overall being 5.45 
mmol/L and for the 45-54 year age group (around the average 
age in the current study) being 5.52 mmol/L.7 Prior diagnoses of 
high cholesterol had been made in 14% with over half receiving 
lipid-lowering, statins or fibrate treatment at the time of screening. 
Another 43% were classified as dyslipidaemic at screening, based 
on the measurement of fasting TC: HDL ratios. Total cholesterol 
and LDL-cholesterol levels were above the recommended ranges, 
but protective HDL-cholesterol levels were also generally above 
the recommended level in this cohort. 
The NZ Cardiovascular Guidelines recommend prescription of 
lipid-lowering, blood-pressure lowering and anticoagulants in those 
with known CVD history. In the current study, 50% of those with 
existing cardiac disease were treated with both lipid-lowering agents 
and antihypertensives. Participants with DM2 and CVD history 
all received combined therapies. Hence, levels of treatment in this 
rural cohort were better than previously published levels of 28% of 
those with CVD history alone,26 and 66% in those with diabetes and 
CVD history.27 Despite high rates of treatment, further treatment 
may be necessary to achieve target thresholds for blood pressure 
and cholesterol.
The proportion of previously diagnosed DM2 in the Wairoa cohort 
was 11%, higher than the self-reported national rate in Māori of 
6%.11 A study of rural Māori reported the rate of known diabetes of 
7% and a further 3.6% were new diagnoses.19 However, the current 
levels were similar to an urban Māori population in The Diabetes 
Heart and Health Survey,10 with prevalence rates of known diabetes 
(12%) and new diagnoses in 4%. In our study, further investigation 
and confirmation of new DM2 was performed by the participant’s 
doctor and are not reported here.
The spectrum of five-year CVD risk scores calculated for this 
cohort are similar to those reported for an urban Māori cohort.28 In 
that study 65.2% were in the 0-10% low CVD risk category, 10.4% 
in the >10-15% moderate CVD risk, 9.9% in the ≥15% high CVD 
risk and 14.4% had very high CVD risk scores ≥20%. The current 
study found relatively more participants (21%) in the moderate risk 
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group and fewer (10%) in the very high risk group. Although derived 
from the Framingham scores, the NZ cardiovascular risk scores are 
not comparable to overseas populations as the algorithm is adjusted 
by adding 5% for individuals from certain high-risk categories, 
including Māori.18 The performance of the NZ risk assessment 
equation in predicting five-year CVD events, particularly for Māori, 
is currently undergoing scrutiny and reconsideration.29-31 A large 
NZ analysis found the adjusted CVD risk scores overestimated 
the observed CVD risk across both high- and low-risk ethnic 
groups.31 In contrast, a separate, large diabetes cohort study found 
CVD events were substantially underestimated by the adjusted risk 
scores in DM2 patients, particularly Māori, and a new CVD risk 
score calculator was proposed.29 Similarly, in The Strong Heart 
Study, a study of the indigenous American Indian population with 
high rates of diabetes and albuminuria, a specific ‘risk calculator’ 
has been developed.32 It is apparent that the derivation of CVD risk 
prediction equations that are equally valid across diverse ethnic 
groups may be challenging.
Since 2003, the guidelines for assessing cardiovascular risk for 
people living in NZ have recommended Māori men be screened 
at five-year intervals from the age of 35 years and Māori women 
from the age of 45 years, a decade earlier than NZ Europeans.18 
Despite these national guidelines, the levels of undiagnosed risk 
factors identified in the current study indicate that systematic risk 
assessment followed by comprehensive risk management is still not 
optimal. A previous comparison of CVD risk in Māori and non-
Māori enrolled in an Auckland primary healthcare organisation,5 
found only 58% of those with known CVD had risk management 
data available.
This study highlights the persistent high rates of cardiovascular 
risk factors in a rural Māori community, particularly obesity, 
hypertension, dyslipidaemia, DM2 and smoking. Treatment of 
cardiovascular morbidities for Māori has greatly improved at 
primary health care level.5 The district is well served with general 
practices and the engagement with the physicians would appear 
to be good, based on the number who had recently attended their 
local doctor. However, this study would suggest that additional 
opportunities to conduct CVD screening could be seized on 
occasions when patients attended their doctor for illness or minor 
injury. Management of risk factors could be intensified further 
to achieve target levels within this rural Māori population. In 
conclusion, the large number of participants with previously 
undiagnosed hypertension and dyslipidaemia indicate that there 
needs to be regular and opportunistic screening of the population 
for blood pressure, cholesterol and diabetes markers, with intensive 
treatment of those risk factors in order to reduce the CVD burden 
on this indigenous group.
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